Long non-coding RNA CRNDE suppressing cell proliferation is regulated by DNA methylation in chronic lymphocytic leukemia.


Journal

Leukemia research
ISSN: 1873-5835
Titre abrégé: Leuk Res
Pays: England
ID NLM: 7706787

Informations de publication

Date de publication:
06 2021
Historique:
received: 14 01 2021
revised: 03 03 2021
accepted: 12 03 2021
pubmed: 16 4 2021
medline: 25 8 2021
entrez: 15 4 2021
Statut: ppublish

Résumé

Long non-coding RNA CRNDE and DNA methylation play a vital role in the occurrence and development of chronic lymphocytic leukemia (CLL). This study attempted to investigate the biological role of CRNDE methylation in CLL. The expression and methylation levels of CRNDE in CLL cell lines (MEC-1 and HG3) before or after methylation inhibitor (5-Aza-2'-deoxycytidine, 5-Aza-CdR) treatment was detected by quantitative real-time PCR or methylation-Specific PCR. The relationship among CRNDE, miR-28 and NDRG2 was verified by luciferase reporter assay. The effect of CRNDE overexpression and 5-Aza-CdR treatment on cell proliferation and apoptosis of MEC-1 and HG3 cells were assessed by CCK8 and flow cytomery. Compared with normal B lymphocytes, CRNDE was down-regulated and the methylation level of CRNDE was increased in MEC-1 and HG3 cells. Then, 5-Aza-CdR treatment caused an increase of CRNDE expression in MEC-1 and HG3 cells by demethylation. The overexpression or demethylation of CRNDE inhibited cell proliferation and promoted apoptosis in MEC-1 and HG3 cells by up-regulating CRNDE expression. Moreover, CRNDE functioned as a competing endogenous RNA to repress miR-28, which controlled its down-stream target NDRG2. CRNDE overexpression inhibited cell proliferation and promoted apoptosis via miR-28/NDRG2 axis in CLL. In conclusion, our data elaborated that CRNDE expression was regulated by DNA methylation, and the protective effect of CRNDE on CLL was attributed to the inhibition of proliferation in CLL via miR-28/NDRG2 axis. Thus, this work highlights a novel competing endogenous RNA circuitry involving key regulators of CLL.

Identifiants

pubmed: 33857783
pii: S0145-2126(21)00065-5
doi: 10.1016/j.leukres.2021.106564
pii:
doi:

Substances chimiques

CRNDE RNA, human 0
MIRN28 microRNA, human 0
MicroRNAs 0
NDRG2 protein, human 0
RNA, Long Noncoding 0
Tumor Suppressor Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106564

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Jing Ni (J)

Department of Hematology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, China.

Jian Hong (J)

Department of Hematology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, China.

Qingsheng Li (Q)

Department of Hematology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, China.

Qingshu Zeng (Q)

Department of Hematology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, China.

Ruixiang Xia (R)

Department of Hematology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, China. Electronic address: xrx2041@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH